Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sagimet Biosciences Inc. - Series A Common Stock
(NQ:
SGMT
)
2.750
-0.010 (-0.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
250,128
Open
2.770
Bid (Size)
2.690 (1)
Ask (Size)
2.960 (1)
Prev. Close
2.760
Today's Range
2.690 - 2.870
52wk Range
2.130 - 20.71
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024
August 14, 2024
SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 14, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Performance
YTD
-48.41%
-48.41%
1 Month
-14.60%
-14.60%
3 Month
-41.98%
-41.98%
6 Month
-60.60%
-60.60%
1 Year
-78.33%
-78.33%
More News
Read More
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
June 10, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
What's Going On With Sagimet Biosciences Stock On Thursday?
June 06, 2024
Via
Benzinga
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
June 06, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
June 05, 2024
Via
Benzinga
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
May 16, 2024
Via
Benzinga
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
May 16, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024
May 15, 2024
Via
InvestorPlace
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 15, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
May 07, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
May 06, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
April 22, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
March 27, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
March 25, 2024
Via
Benzinga
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
March 17, 2024
Via
The Motley Fool
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
February 29, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
February 16, 2024
Via
Benzinga
Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 06, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 06, 2024
Via
Benzinga
Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China
January 27, 2024
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.